SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kosan BioSciences -- KOSN
An SI Board Since May 2001
Posts SubjectMarks Bans Symbol
933 40 0 KOSN
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
883>> Helen Kim takes CEO position << President position, sorry. Archscaram(o)uche-2/28/2008
882missed everything but the end of M. King's last question and the next five mscaram(o)uche-2/28/2008
881>> Still don't agree with their methods of reprioritizing << Wescaram(o)uche-2/28/2008
880OK, their resources weren't going to last much over a year had they kept alltuck-2/28/2008
879>>Kosan Announces Senior Management Changes and Clinical Portfolio Priorittuck-2/28/2008
878Helen Kim takes CEO position, Johnson out. Follow-on hsp90 inhibitor dropped (&scaram(o)uche-2/28/2008
877I bought today, just a tad. Was watching and hoping for a "sign". Hescaram(o)uche-2/27/2008
876>>Did you buy any?<< No, thank goodness. I now have a GTC order fotuck-2/27/2008
875[Silencing of HSP90 cochaperone AHA1 expression decreases client protein activattuck-2/23/2008
874snta is a competitor with an earlier synthetic hsp 90. Probably doubtful theyrkrw-2/10/2008
873[Stage 1 testing and pharmacodynamic evaluation of 17-DMAG by the pediatric prectuck-2/10/2008
872>>Are things really that bad at Kosan? Today had the feel of some institutIcebrg-1/23/2008
871[Inhibition of Hsp90 down-regulates mutant EGFR expression and sensitizes EGFR mtuck-1/21/2008
870All time low today, not even a buck above cash. Are things really that bad at Ktuck-1/17/2008
869[17-AAG & Carboplatin versus ovarian cancer] >>Cancer Chemother Pharmtuck-1/16/2008
868Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitormopgcw-1/15/2008
8672008 Infinity Goals and Financial Guidance * Launch a Phase 3 registration triaIcebrg-1/7/2008
866>>Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma Last updatetuck-1/3/2008
865Kosan Appoints Helen S. Kim as Chief Business Officer Thursday January 3, 6:00 aIcebrg-1/3/2008
864[Combo of 17-AAG and CDc37 inhibition versus prostate cancer] >>Cancer Retuck-12/20/2007
863Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in PatientIcebrg-12/17/2007
862I could it being hard to break into that regimen. Thanks.keokalani'nui-12/12/2007
8613-Drug Combination 'Extremely Promising' As First-Line Therapy For Multirkrw-12/12/2007
860Kosan Shares Fall on Cancer Study Data Monday December 10, 6:33 pm ET Kosan BiosIcebrg-12/11/2007
859I reloaded another slug to trade here. I think it is a broad portfolio and volatmopgcw-12/10/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News